The signaling mechanism of anti-PD-1/PD-L1 involves triggering the activation of cytotoxic CD4+/CD8+ T cells and subsequent killing of cancer cells, causing specific immunological side effects specific to the inhibitors of both PD-1 and PD-L1 [33,34]. This evidence concerns the gene CD274 and cancer.